Novartis has increased its pharmaceutical stockpiles in the U.S. to prepare for potential tariffs from President Trump. The industry awaits the outcome of an investigation that could lead to import duties. Despite exemptions, a U.S.-EU trade deal includes a 15% tariff on pharmaceuticals. Novartis plans $23 billion in U.S. investments to shift production locally. CEO Narasimhan aims to mitigate any potential tariffs. The impact of possible 250% tariffs remains uncertain pending investigation results. Novartis is preparing for various scenarios but lacks clarity until the investigation concludes.

Read more at Yahoo Finance: Novartis has stockpiles to withstand potential Trump tariffs, CEO says